Labeling Requirements for IMPs Amended

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Following a 1-month feedback period on the draft published in June this year the European Commission (EC) finally adopted on 6 September the revised Annex VI to Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR) as regards labelling requirements for IMPs. The Regulation will enter into force on the twentieth day following its publication in the Official Journal of the European Union and will be binding and directly applicable in all Member States.
Background
The Commission Delegated Regulation amending the CTR as regards labelling requirements for unauthorized investigational (IMPs) and unauthorized auxiliary medicinal products (AxMPs) eliminates the obligation to include an expiry date on the primary packaging of IMPs / AxMPs in specific circumstances.
Feedback received from business organizations and companies on the draft delegated regulation, supported in majority the proposed rules. Some of these contributors proposed additional labelling exemptions, which were not considered due to the potential safety impact on clinical trial participants. Contributions were also received from citizens, who expressed their concerns. These concerns were mainly due to misunderstandings about the proposed rules, which were often understood as exemptions to label the expiry date for medicines or allowing unauthorized medicines to be put on the market. As a consequence, the draft Regulation was not amended after consultation.
The final Delegated Regulation and its Annex can be downloaded from the Commission's website, where the comments (including comments from EQPA's IMP Working Group) are also available.
More information is provided under Unauthorised medicinal products used in clinical trials (labelling rules).
Related GMP News
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification
10.09.2025Why Human Error is not the End but the Beginning: Rethinking Deviation Management
03.09.2025Is QP Release possible after deviating In-Process Controls?